Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. / Viby, Niels-Erik; Isidor, Marie Sophie; Buggeskov, Katrine B; Poulsen, Steen Seier; Hansen, Jacob B.; Kissow, Hannelouise.

In: Endocrinology, Vol. 154, No. 12, 2013, p. 4503-4511.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Viby, N-E, Isidor, MS, Buggeskov, KB, Poulsen, SS, Hansen, JB & Kissow, H 2013, 'Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice', Endocrinology, vol. 154, no. 12, pp. 4503-4511. https://doi.org/10.1210/en.2013-1666

APA

Viby, N-E., Isidor, M. S., Buggeskov, K. B., Poulsen, S. S., Hansen, J. B., & Kissow, H. (2013). Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology, 154(12), 4503-4511. https://doi.org/10.1210/en.2013-1666

Vancouver

Viby N-E, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013;154(12):4503-4511. https://doi.org/10.1210/en.2013-1666

Author

Viby, Niels-Erik ; Isidor, Marie Sophie ; Buggeskov, Katrine B ; Poulsen, Steen Seier ; Hansen, Jacob B. ; Kissow, Hannelouise. / Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. In: Endocrinology. 2013 ; Vol. 154, No. 12. pp. 4503-4511.

Bibtex

@article{b1badcef622341ab8eb2515cb8f2d65d,
title = "Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice",
abstract = "The incretin hormone glucagon-like peptide-1 (GLP-1) is an important insulin secretagogue and GLP-1 analogues are used for the treatment of type 2 diabetes. GLP-1 displays anti-inflammatory and surfactant releasing effects. Thus, we hypothesize that treatment with GLP-1 analogues will improve pulmonary function in a mouse model of obstructive lung disease. Female mice were sensitized with injected ovalbumin and treated with GLP-1 receptor (GLP-1R) agonists. Exacerbation was induced with inhalations of ovalbumin and lipopolysaccharide. Lung function was evaluated with measurement of enhanced pause (Penh) in a whole body plethysmograph. mRNA levels of GLP-1R, surfactants (SFTPs), and a number of inflammatory markers were measured. GLP-1R was highly expressed in lung tissue. Mice treated with GLP-1R agonists had a noticeably better clinical appearance than the control group. Penh increased dramatically at day 17 in all control mice but the increase was significantly less in the groups of GLP-1R agonist treated mice (p",
author = "Niels-Erik Viby and Isidor, {Marie Sophie} and Buggeskov, {Katrine B} and Poulsen, {Steen Seier} and Hansen, {Jacob B.} and Hannelouise Kissow",
year = "2013",
doi = "10.1210/en.2013-1666",
language = "English",
volume = "154",
pages = "4503--4511",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "Oxford University Press",
number = "12",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice

AU - Viby, Niels-Erik

AU - Isidor, Marie Sophie

AU - Buggeskov, Katrine B

AU - Poulsen, Steen Seier

AU - Hansen, Jacob B.

AU - Kissow, Hannelouise

PY - 2013

Y1 - 2013

N2 - The incretin hormone glucagon-like peptide-1 (GLP-1) is an important insulin secretagogue and GLP-1 analogues are used for the treatment of type 2 diabetes. GLP-1 displays anti-inflammatory and surfactant releasing effects. Thus, we hypothesize that treatment with GLP-1 analogues will improve pulmonary function in a mouse model of obstructive lung disease. Female mice were sensitized with injected ovalbumin and treated with GLP-1 receptor (GLP-1R) agonists. Exacerbation was induced with inhalations of ovalbumin and lipopolysaccharide. Lung function was evaluated with measurement of enhanced pause (Penh) in a whole body plethysmograph. mRNA levels of GLP-1R, surfactants (SFTPs), and a number of inflammatory markers were measured. GLP-1R was highly expressed in lung tissue. Mice treated with GLP-1R agonists had a noticeably better clinical appearance than the control group. Penh increased dramatically at day 17 in all control mice but the increase was significantly less in the groups of GLP-1R agonist treated mice (p

AB - The incretin hormone glucagon-like peptide-1 (GLP-1) is an important insulin secretagogue and GLP-1 analogues are used for the treatment of type 2 diabetes. GLP-1 displays anti-inflammatory and surfactant releasing effects. Thus, we hypothesize that treatment with GLP-1 analogues will improve pulmonary function in a mouse model of obstructive lung disease. Female mice were sensitized with injected ovalbumin and treated with GLP-1 receptor (GLP-1R) agonists. Exacerbation was induced with inhalations of ovalbumin and lipopolysaccharide. Lung function was evaluated with measurement of enhanced pause (Penh) in a whole body plethysmograph. mRNA levels of GLP-1R, surfactants (SFTPs), and a number of inflammatory markers were measured. GLP-1R was highly expressed in lung tissue. Mice treated with GLP-1R agonists had a noticeably better clinical appearance than the control group. Penh increased dramatically at day 17 in all control mice but the increase was significantly less in the groups of GLP-1R agonist treated mice (p

U2 - 10.1210/en.2013-1666

DO - 10.1210/en.2013-1666

M3 - Journal article

VL - 154

SP - 4503

EP - 4511

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 12

ER -

ID: 57754734